###begin article-title 0
###xml 21 32 21 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">"Endoglin" </italic>
###xml 36 67 36 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">"Activin receptor-like kinase" </italic>
###xml 83 91 <span type="species:ncbi:9606">patients</span>
Mutation analysis of "Endoglin" and "Activin receptor-like kinase" genes in German patients with hereditary hemorrhagic telangiectasia and the value of rapid genotyping using an allele-specific PCR-technique
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 331 334 331 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG</italic>
###xml 393 399 393 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1</italic>
###xml 543 547 543 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 551 558 551 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
###xml 683 687 683 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 727 734 727 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
###xml 471 479 <span type="species:ncbi:9606">patients</span>
###xml 571 579 <span type="species:ncbi:9606">patients</span>
Hereditary hemorrhagic telangiectasia (HHT), also known as Rendu-Osler-Weber syndrome, is an autosomal dominant disorder which is clinically characterised by recurrent epistaxis, mucocutaneous telangiectasia and visceral arteriovenous malformations. Genetic linkage studies identified two genes primarily related to HHT: endoglin (ENG) on chromosome 9q33-34 and activin receptor-like kinase1 (ACVRL1) on chromosome 12q13. We have screened a total of 41 unselected German patients with the suspected diagnosis of HHT. Mutation analysis for the ENG and ACVRL1 genes in all patients was performed by PCR amplification. Sequences were then compared to the HHT database  sequences of the ENG mRNA (accession no. BC014271.2) and the ACVRL1 mRNA (accession no. NM000020.1).
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 104 108 104 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 326 330 326 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 362 369 362 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
###xml 312 320 <span type="species:ncbi:9606">patients</span>
###xml 348 356 <span type="species:ncbi:9606">patients</span>
We identified 15 different mutations in 18 cases by direct sequencing. Among these mutations, one novel ENG mutation could be detected which has not yet been described in the literature before. The genotype-phenotype correlation was consistent with a higher frequency of pulmonary arteriovenous malformations in patients with ENG mutations than in patients with ACVRL1 mutations in our collective.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 80 84 80 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 88 94 88 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1</italic>
For rapid genotyping of mutations and SNPs (single nucleotide polymorphisms) in ENG and ACVRL1, allele-specific PCR methods with sequence-specific primers (PCR-SSP) were established and their value analysed.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 221 222 221 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 223 224 223 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 646 647 646 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 660 661 660 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 677 678 677 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 684 685 684 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 686 687 686 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 847 849 847 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 850 852 850 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1015 1017 1015 1017 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
Hereditary hemorrhagic telangiectasia (HHT, MIM#18730), also known as Rendu-Osler-Weber syndrome, is an autosomal dominant disorder of the fibrovascular tissue. Worldwide, HHT has a prevalence of 1 in 10.000 individuals [1,2]. This multi-systemic angiogenic disorder is clinically characterized by severe and recurrent hemorrhages due to epistaxis, mucocutaneous telangiectasia and arteriovenous malformations. Vascular lesions are present in two forms, either as telangiectases on the skin as well as the inner lining of the mouth, nose and gastrointestinal tract (GI-tract) and/or as direct arteriovenous shunts most commonly seen in the lung (PAVM), brain (CAVM) and liver (HAVM) [3-9]. Electron microscopy studies on lesion biopsies revealed that dilated postcapillary venules connect directly to arterioles without intervening capillary bed [10,11]. As a result, these vascular lesions can be the cause for severe complications involving gastrointestinal bleedings, the risk of embolism, stroke and abscesses [12].
###end p 9
###begin p 10
###xml 174 176 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 53 61 <span type="species:ncbi:9606">patients</span>
Till now, HHT can not be cured. The treatment of HHT patients remains symptomatic or has preventive character. The Curacao criteria are in clinical use for diagnosis of HHT [13]. However, the clinical manifestations of HHT can be very heterogeneous, both between families and among members of the same family, making the diagnosis of the disease at times very difficult.
###end p 10
###begin p 11
###xml 119 123 119 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 138 145 138 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
###xml 215 217 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 218 220 218 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 249 252 249 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG</italic>
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 387 389 387 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 513 519 513 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1</italic>
###xml 535 537 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 538 540 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 700 702 700 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 703 705 703 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 886 888 886 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 889 891 889 891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 933 937 933 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 941 948 941 948 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
###xml 1004 1006 1004 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1139 1141 1139 1141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1179 1181 1179 1181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1332 1334 1332 1334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1260 1268 <span type="species:ncbi:9606">patients</span>
In the 90s, genetic linkage studies revealed the two major types of disease, HHT1 and HHT2, caused by mutations in the ENG (endoglin) and ACVRL1 genes. The first locus (HHT type 1) was mapped to chromosome 9q33-34 [14,15], where the 40 kb endoglin (ENG, OMIM 187300) was defined as the affected gene [16], also associated with a high prevalence of pulmonary arteriovenous malformations [17]. The second locus (HHT type 2) mapping to chromosome 12q was identified as the 15 kb activin receptor-like kinase-1 gene (ACVRL1, OMIM 600376) [18,19]. It is characterised by a lower incidence of pulmonary and cerebral arteriovenous malformations than HHT1, but has a higher incidence of liver manifestation [17,20]. The corresponding endoglin and ALK-1 proteins are specific endothelial receptors of the transforming growth factor beta superfamily essential for maintaining vascular integrity [21,22]. Many mutations have been identified in ENG and ACVRL1 genes and support the haploinsufficiency model for HHT [23]. In recent studies, two more genes have been implicated in HHT, which have not yet been identified, the HHT3 gene on chromosome 5 [24], and the HHT4 gene on chromosome 7 [25]. In addition, SMAD4 mutations mapping to chromosome 18 have been observed in patients with a combined syndrome of juvenile polyposis and HHT (JPHT) [26].
###end p 11
###begin p 12
###xml 67 71 67 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 75 82 75 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
###xml 158 162 158 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 174 182 <span type="species:ncbi:9606">patients</span>
In this study, we report mutational analysis of the two main genes ENG and ACVRL1 in a German population affected by HHT. We describe a novel mutation in the ENG gene in HHT patients which has not been described before. Furthermore, we determine the value of allele-specific PCR for rapid genotyping.
###end p 12
###begin title 13
Methods
###end title 13
###begin title 14
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and controls
###end title 14
###begin p 15
###xml 338 339 338 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 435 436 435 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 924 926 924 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 945 946 945 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
###xml 63 71 <span type="species:ncbi:9606">patients</span>
###xml 350 358 <span type="species:ncbi:9606">patients</span>
###xml 395 402 <span type="species:ncbi:9606">persons</span>
###xml 630 637 <span type="species:ncbi:9606">patient</span>
###xml 1023 1031 <span type="species:ncbi:9606">patients</span>
Anti-coagulated peripheral blood samples were obtained from 41 patients of German origin with tentative diagnosis of HHT at the Department of ORL, Head and Neck Surgery, University Hospital Mannheim, and from 768 healthy blood donors as a control group from the Institute of Transfusion Medicine and Immunology, Mannheim (Additional file 1). The HHT patients comprised 4 small-sized families (3 persons each) and 29 single cases (Fig. 1). Information on the clinical data including the medical history, physical examination and diagnostic screening was obtained in personal interviews with the affected individuals and from their patient records with all the data being documented in an HHT database. According to the Curacao criteria, diagnosis for HHT included the presence of three out of four key symptoms: recurrent epistaxis, telangiectasia, hereditary with an affected first degree relative and visceral involvement [13] (Additional file 2). An informed consent was obtained from each individual and from parents of patients younger than 18 years according to the approval of the Ethic Committee of the University of Mannheim.
###end p 15
###begin p 16
###xml 0 45 0 45 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Pedigree of the four small-sized HHT families</bold>
Pedigree of the four small-sized HHT families. White square and white circle = unaffected, grey square and grey circle = affected, X = DNA available, # = Pat.-no.
###end p 16
###begin title 17
Isolation of DNA
###end title 17
###begin p 18
DNA was extracted from anti-coagulated peripheral blood samples using a commercial DNA isolation kit (QIAamp DNA blood mini kit; Qiagen, Hilden, Germany) according to the standard protocol.
###end p 18
###begin title 19
###xml 14 18 14 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 22 29 22 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
Sequencing of ENG and ACVRL1 exons
###end title 19
###begin p 20
###xml 56 60 56 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 64 71 64 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 606 610 573 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 629 636 596 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
###xml 795 799 762 764 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 808 810 773 775 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 919 923 884 888 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 963 970 928 935 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
###xml 657 665 <span type="species:ncbi:9606">patients</span>
All coding exons and flanking intronic sequences of the ENG and ACVRL1 genes were PCR amplified using primers published previously [27,28]. PCR was performed in a total volume of 50 mul including 100 ng DNA, 0.5 muM each primer, 200 muM each dNTP, standard PCR buffer (Qiagen) and 1 U HotStar Taq DNA polymerase (Qiagen). The cycling parameters were as follows: initial denaturation for 15 min at 95degreesC; 35 cycles with 20 sec. at 94degreesC, 30 sec. at 60degreesC and 60 sec. at 72degreesC; final extension for 5 min at 72degreesC. After the PCR, products were run on 2% agarose gels. The 15 exons of ENG and the 9 exons of ACVRL1 were sequenced in 41 patients with HHT using Thermosequenase reagents (GE Healthcare Amersham), IRD700 and IRD800 labelled primers and an automated system (NEN(R) Global IR2 DNA Sequencer; LI-COR inc., Lincoln, NE, USA). Sequences were compared to the HHT database  sequences of the ENG mRNA (accession no. BC014271.2) and the ACVRL1 mRNA (accession no. NM000020.1).
###end p 20
###begin title 21
PCR-SSP typing of SNPs
###end title 21
###begin p 22
###xml 50 54 50 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 58 64 58 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1</italic>
###xml 234 235 234 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S3">3</xref>
###xml 370 372 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 373 375 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
For rapid genotyping of the mutations and SNPs in ENG and ACVRL1, allele-specific PCR methods with sequence-specific primers (PCR-SSP) were established. Specific primer sequences and sizes of PCR products are given in Additional file 3. Part of the beta-globin locus was amplified as an internal control PCR fragment (540 bp). According to a published PCR-SSP protocol [29,30], 20 ng DNA were subjected to 10 mul PCR reactions including 0.5 muM each allele-specific primers, 0.1 muM each internal control primer, standard PCR buffer (Qiagen), 200 muM each dNTP and 0.5 units Taq DNA polymerase (Qiagen). The cycling conditions were: 2 min initial denaturation at 94degreesC, followed by 10 cycles with 20 s denaturation at 94degreesC and 1 min annealing/extension at 65degreesC, followed by 20 cycles with 20 s duration at 94degreesC, 1 min annealing at 61degreesC and 30 s extension at 72degreesC. Amplification products were separated on 2% agarose gels containing 0.5 ng/ml ethidium bromide in a rapid agarose gel electrophoresis (RAGE; Cascade Biologics, Inc., Portland, OR, USA) chamber for 5 min at 25 V/cm. Results were obtained by visual inspection of the gels and were documented by using a UV documentation device with CCD camera (UVP, Inc., Upland, CA, USA).
###end p 22
###begin title 23
Results
###end title 23
###begin p 24
###xml 27 31 27 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 59 66 59 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
###xml 224 228 224 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 232 239 232 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
###xml 148 156 <span type="species:ncbi:9606">patients</span>
The 15 coding exons of the ENG gene and the 9 exons of the ACVRL1 gene including flanking intron sequences were PCR amplified and sequenced from 41 patients with HHT. The sequence data were compared to each other and to the ENG and ACVRL1 sequences published in databases (HHT Mutation Database: ). Mutations could be detected in 18 cases (43.9%).
###end p 24
###begin title 25
###xml 21 24 21 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG</italic>
Sequence analysis of ENG
###end title 25
###begin title 26
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
ENG mutations
###end title 26
###begin p 27
###xml 26 30 26 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 85 89 85 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 202 203 202 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S4">4</xref>
###xml 283 287 283 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 472 476 472 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 627 628 627 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 59 67 <span type="species:ncbi:9606">patients</span>
We identified 5 different ENG mutations in 6 out of 41 HHT patients. The 5 different ENG mutations represented: 1 deletion, 1 insertion, 2 splice site mutations and 1 missense mutation (Additional file 4). In our study, mutation c.816+2T>C was detected in 2 related cases. One novel ENG mutation was detected in exon 10 (c.1384insT) causing a frameshift (p.Gln462fs) which has not yet been listed in the HHT gene database before. Altogether, all of the mutations found in ENG were detected in exons coding for the extracellular protein-domain. No mutations were detected in the region coding for the intracellular domain (Fig. 2).
###end p 27
###begin p 28
###xml 33 37 33 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 0 41 0 41 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Distribution of mutations in the <italic>ENG </italic>gene</bold>
Distribution of mutations in the ENG gene. Novel mutation is given in bold.
###end p 28
###begin title 29
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
Polymorphisms in the ENG gene
###end title 29
###begin p 30
###xml 79 83 79 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 121 122 121 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S5">5</xref>
###xml 236 244 <span type="species:ncbi:9606">patients</span>
###xml 258 266 <span type="species:ncbi:9606">patients</span>
###xml 397 405 <span type="species:ncbi:9606">patients</span>
###xml 513 520 <span type="species:ncbi:9606">patient</span>
The 5 different polymorphisms and their relative frequencies identified in the ENG gene are presented in Additional file 5. A previously reported G to A substitution at position 207 of exon 2 (c.207G>A) was observed in 12 out of 41 HHT patients (29.3%). Two patients carried a c.1844C>T polymorphism in exon 13 (4.8%). At position 1029 (c.1029C>T) of exon 8, a C to T change was observed in 7 HHT patients (17%). A c.1347A>G polymorphism in exon 10 and a c.1771G>A polymorphism in exon 13 was observed in one HHT patient (2.4%).
###end p 30
###begin title 31
###xml 21 27 21 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1</italic>
Sequence analysis of ACVRL1
###end title 31
###begin title 32
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
ACVRL1 mutations
###end title 32
###begin p 33
###xml 14 21 14 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
###xml 183 184 183 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S6">6</xref>
###xml 390 397 390 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
###xml 499 506 499 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
###xml 581 582 581 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 71 79 <span type="species:ncbi:9606">patients</span>
Ten different ACVRL1 mutations could be identified in 12 out of 41 HHT patients, including 2 deletions, 2 insertions, 1 splice site mutation and 5 missense mutations (Additional file 6). The insertion c.144_145insG (p.Ala49fs) was detected in 2 members of the same family, whereas the missense mutation c.1120C>T (p.Arg374Trp) was detected in 2 unrelated cases. Half of the HHT2 associated ACVRL1 mutations consisted of single base substitutions, leading to amino acid changes. More than 75% of all ACVRL1 mutations were detected in exons coding for the intracellular domain (Fig. 3). Especially four out of five missense mutations (80%) were found in the receptor domain or the kinase domain, mainly affecting exon 8. No mutations were detected in the region coding for the transmembrane domain.
###end p 33
###begin p 34
###xml 33 40 33 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
###xml 0 44 0 44 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Distribution of mutations in the <italic>ACVRL1 </italic>gene</bold>
Distribution of mutations in the ACVRL1 gene.
###end p 34
###begin title 35
###xml 19 23 19 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 27 34 27 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
PCR-SSP typing for ENG and ACVRL1 mutations
###end title 35
###begin p 36
###xml 169 176 169 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
###xml 194 198 194 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 488 489 488 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 871 875 871 875 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 879 886 879 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
###xml 983 987 983 987 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 990 997 990 997 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
###xml 114 122 <span type="species:ncbi:9606">patients</span>
###xml 241 249 <span type="species:ncbi:9606">patients</span>
Further investigation on allele and genotype frequencies focused on the mutations identified in our cohort of HHT patients. PCR-SSP systems could be established for all ACVRL1 mutations and all ENG mutations. A panel of DNA samples from HHT patients with different mutations was selected on the basis of the sequencing data and was used to validate all 15 PCR-SSP systems. The genotypes were estimated on the basis of the presence or the absence of the allele-specific PCR products (Fig. 4). All of the 41 HHT samples were retyped by PCR-SSP and data were compared to sequencing data. We could achieve 100% concordance of data, i.e. DNA samples with mutation revealed a positive PCR signal in the corresponding PCR-SSP system and DNA samples without mutation were negative in all 15 PCR-SSP systems. In addition, the 15 PCR-SSP systems were applied for genotyping of the ENG and ACVRL1 mutations in 768 healthy blood donor controls. None of the healthy control individuals showed an ENG or ACVRL1 mutation indicating the specificity of the gene variants for the HHT phenotype.
###end p 36
###begin p 37
###xml 58 62 58 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 70 77 70 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
###xml 0 90 0 90 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Representative results from PCR-SSP analysis of different <italic>ENG </italic>(A) and <italic>ACVRL1 </italic>(B) mutations</bold>
###xml 127 131 127 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 177 184 177 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
###xml 406 413 <span type="species:ncbi:9606">patient</span>
Representative results from PCR-SSP analysis of different ENG (A) and ACVRL1 (B) mutations. Three of the 5 PCR-SSP systems for ENG mutations and 4 of the 10 PCR-SSP systems for ACVRL1 mutations are shown as examples. The specificity of PCR-SSP for the corresponding mutations was given by the absence of the specific PCR product in healthy controls (each lane 1) and presence of the PCR product in the HHT patient (each lane 2). The internal control fragment of 540 bp in size (arrow head) was present in each reaction (or at least where the PCR-SSP product was absent).
###end p 37
###begin title 38
Phenotype-Genotype Correlation
###end title 38
###begin p 39
###xml 365 367 365 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 927 931 927 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 971 977 971 977 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1</italic>
###xml 1086 1087 1086 1087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S7">7</xref>
###xml 374 382 <span type="species:ncbi:9606">patients</span>
###xml 569 577 <span type="species:ncbi:9606">patients</span>
###xml 634 642 <span type="species:ncbi:9606">patients</span>
###xml 819 827 <span type="species:ncbi:9606">patients</span>
###xml 839 847 <span type="species:ncbi:9606">patients</span>
###xml 896 904 <span type="species:ncbi:9606">patients</span>
###xml 938 946 <span type="species:ncbi:9606">patients</span>
###xml 1025 1033 <span type="species:ncbi:9606">patients</span>
Diagnosis of HHT in an individual required that they met three or more of the following four Curacao criteria: 1) spontaneous and recurrent epistaxis, 2) mucocutaneous telangiectasias, 3) organ manifestation with arteriovenous malformations (AVMs) including pulmonary, cerebral, hepatic, gastrointestinal and/or 4) hereditary with a first-degree relative with HHT [13]. All patients included in this study either met the criteria for manifest clinical diagnosis or suspected clinical diagnosis of HHT with at least three or two criteria present. Altogether, 71% of the patients (29 out of 41) had a manifest HHT diagnosis. All of the patients had as main clinical symptom recurrent epistaxis and a positive family history of HHT, followed by telangiectasias in 65.8% and AVMs of any type in 56% of the cases. Of the 41 patients tested, 18 patients were found to have sequence alterations, with 6 patients showing mutations for ENG and 12 patients revealing mutations for ACVRL1. The genotype-phenotype correlation of all HHT patients with confirmed mutation is given in Additional file 7.
###end p 39
###begin title 40
Discussion
###end title 40
###begin p 41
###xml 11 15 11 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 53 60 53 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
###xml 344 348 344 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 352 359 352 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
###xml 393 395 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 396 398 396 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 374 382 <span type="species:ncbi:9606">patients</span>
Presently, ENG (endoglin) on chromosome 9q33-q34 and ACVRL1 (activin-receptor-like kinase) on chromosome 12q13 are the two genes primarily implicated in the development of Hereditary Hemorrhagic Telangiectasia (HHT). In literature, frequent mutations in both genes have been detected in different case studies indicating a common occurrence of ENG and ACVRL1 DNA changes in patients with HHT [27,28].
###end p 41
###begin p 42
###xml 156 160 156 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 164 171 164 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
###xml 740 742 740 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 743 745 743 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 746 748 746 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 791 798 791 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
###xml 938 942 938 942 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 977 981 977 981 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 1244 1245 1244 1245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 1246 1247 1246 1247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1248 1250 1248 1250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1251 1253 1251 1253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1254 1256 1254 1256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1257 1259 1257 1259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1479 1483 1479 1483 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 1607 1610 1607 1610 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG</italic>
###xml 1784 1790 1784 1790 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1</italic>
###xml 1886 1893 1886 1893 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
###xml 1921 1923 1921 1923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1924 1926 1924 1926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1993 2000 1993 2000 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
###xml 2284 2291 2284 2291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
###xml 2398 2400 2398 2400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 2401 2403 2401 2403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 2404 2406 2404 2406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 2407 2409 2407 2409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 2547 2551 2547 2551 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 2555 2562 2555 2562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
###xml 2700 2702 2700 2702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 2703 2705 2703 2705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 2706 2708 2706 2708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 30 38 <span type="species:ncbi:9606">patients</span>
###xml 217 225 <span type="species:ncbi:9606">patients</span>
###xml 304 312 <span type="species:ncbi:9606">patients</span>
###xml 455 463 <span type="species:ncbi:9606">patients</span>
###xml 517 525 <span type="species:ncbi:9606">patients</span>
###xml 608 616 <span type="species:ncbi:9606">patients</span>
###xml 852 860 <span type="species:ncbi:9606">patients</span>
###xml 1428 1436 <span type="species:ncbi:9606">patients</span>
In a consecutive series of 41 patients, we performed clinical genetic testing for the two major types of disease, HHT1 and HHT2, caused by mutations in the ENG and ACVRL1 gene sequence for HHT. The series included 29 patients with clinical diagnosis of HHT who met three or more clinical features and 12 patients with suspected diagnosis with two clinical features according to the Curacao criteria. The mutation detection rate in our series of 41 German patients was 44%. Based on the Curacao criteria, 15 of the 18 patients (83%) with a mutation had a manifest clinical HHT diagnosis, with the remaining 3 patients (17%) fulfilling two criteria. This rate is similar to other studies which have been consistently described in literature [17,27,28]. Most of the mutations were found in the ACVRL1 gene with a total of 10 different mutations in 12 HHT patients whereas a total of 5 mutations were identified in the coding sequence of the ENG gene in 6 individuals. Most of the ENG mutations were widely distributed throughout the gene, not indicating any special hot spot areas within the gene. Out of five detected DNA changes, four mutations had been described previously as mutations in the HHT mutation database or recently been published [2,5,20,27,31-35]. The alterations included mainly nucleotide substitutions such as missense, splice site and frameshift mutations. In spite of the fact that only a small series of HHT patients was investigated in this study, one novel ENG mutation c.1384insT (p.Gln462fs) could be detected which had not been described before in the HHT mutation database. Unlike ENG, 50% of the mutations in the ACVRL1 gene were missense substitutions. Similar results had been published by Abdalla et al. who analysed all 123 till then known mutations of ACVRL1. In their study overview they could also register more than half (53%) of the mutations in the ACVRL1 gene as missense mutations [36,37]. As previously described in other HHT families, the frequency of ACVRL1 mutations was highest in exon 8 which might be an indicator for mutation hotspots. The other mutations c.144_145insG (p.Ala49fs), c.200G>A (p.Arg67Gln), c.540_541insA (p.Asp181fs), c.673_674delAG (p.Ser225fs), c.696_698delCTC (p.Ser233del), c.1346C>T (p.Pro449Leu) and c.1377+1G>A in ACVRL1 were already described by other workgroups, mostly located in the intracellular kinase domain of the gene [28,35,37-40]. Only two already known mutations could be detected in the extracellular domain of the gene. However, large deletions and insertions in ENG and ACVRL1 were not analyzed which could explain the low detection rate of mutations in our study compared to other studies described in literature [28,32,36].
###end p 42
###begin p 43
###xml 110 111 110 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 179 182 179 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG</italic>
###xml 294 298 294 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 367 368 367 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 395 400 395 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ALK1 </italic>
###xml 471 472 471 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 538 539 538 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 540 541 540 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 542 544 542 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 545 547 545 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 607 614 607 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
###xml 733 737 733 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 741 748 741 748 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
###xml 151 159 <span type="species:ncbi:9606">patients</span>
###xml 593 601 <span type="species:ncbi:9606">patients</span>
###xml 719 727 <span type="species:ncbi:9606">patients</span>
As far as the genotype-phenotype correlation is concerned, most of the pulmonary arteriovenous malformations (PAVMs) in our study were detected in HHT patients with mutations for ENG. This phenomenon has already been described by previous studies given in literature, stating that mutations of ENG are mainly observed in HHT type 1 with an incidence of up to 40% for PAVMs, whereas mutations of ALK1 are primarily observed in HHT type 2 with an incidence of only 14% for PAVMs, which clinically distinguishes these two types of mutation [3,7,28,36]. Liver manifestations were more frequent in patients with ACVRL1 mutations, whereas manifestations of the skin and the GI-tract were seen equally distributed amongst HHT patients with ENG and ACVRL1 mutations.
###end p 43
###begin p 44
###xml 60 62 60 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 63 65 63 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 66 68 66 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 453 457 453 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 461 468 461 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
###xml 607 609 607 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 610 612 610 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 180 188 <span type="species:ncbi:9606">patients</span>
###xml 294 302 <span type="species:ncbi:9606">patients</span>
###xml 369 377 <span type="species:ncbi:9606">patients</span>
Many studies report a mutation detection rate of up to 92% [27,28,33]. However, in our study we were able to identify only 43.9% of disease-causing mutations in a series of 41 HHT patients. The difference in sensitivity may result from several factors, including a very heterogeneous cohort of patients in terms of locations and initial physician involved, and because patients with only 2 Curacao criteria were included in the study. In addition, only ENG and ACVRL1 genes were screened for mutations, but in some cases, mutations in SMAD4, HHT3 and HHT4 loci may be responsible for the clinical symptoms [24-26].
###end p 44
###begin p 45
###xml 791 795 791 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 799 806 799 806 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
###xml 910 914 910 914 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 1102 1110 <span type="species:ncbi:9606">patients</span>
In daily clinical routine, the diagnosis of HHT is primarily based on the clinical findings according to the Curacao criteria. Nevertheless, in many cases clinical diagnostic is at times very difficult due to the heterogeneous outcome and manifestation of the disease. This fact asks for additional diagnostic tools which facilitate the daily clinical work. Already in the past, many studies could show that the molecular characterization of HHT enables to predict the diagnosis before the manifestation of clinical symptoms. The results of the study reflect the very high and heterogenic distribution and allocation of mutations in HHT. With an allele-specific PCR technique (PCR-SSP) we could establish a diagnostic testing device for rapid genotyping of mutations. The exon sequencing of ENG and ACVRL1 confirmed the previously described polymorphisms and outlined one novel mutation Gln462fs in exon 10 of ENG gene. The PCR-SSP technique can easily be performed with standard laboratory equipment and may help to minimize costs for genetic testing in the routine diagnosis of family members of HHT patients with known mutations.
###end p 45
###begin title 46
Conclusion
###end title 46
###begin p 47
###xml 87 91 87 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 95 102 95 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
###xml 150 154 150 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 312 320 <span type="species:ncbi:9606">patients</span>
###xml 355 363 <span type="species:ncbi:9606">patients</span>
In summary, this study is a further contribution to the determination of already known ENG and ACVRL1 mutations as well as the detection of one novel ENG mutation in HHT. Next to the Curacao criteria, genetic analysis certainly contributes as an essential tool to a reliable diagnosis of clinically affected HHT patients and clinically un-symptomatic HHT patients, thus helping to take early preventive measures even before the occurrence of first clinical symptoms. The PCR-SSP technique could facilitate this high task of genetic analysis in routine HHT diagnostics and underlines the importance of using molecular diagnosis for early identification of individuals carrying mutations and being at risk of vascular complications.
###end p 47
###begin title 48
Competing interests
###end title 48
###begin p 49
The authors declare that they have no competing interests.
###end p 49
###begin title 50
Authors' contributions
###end title 50
###begin p 51
All the authors have read and approved the final manuscript. A large part of the mutational analysis was done by HS, JH under the supervision of PB. The rest of the mutational analysis was done by UG, JS, KH completing the analysis of mutations. Bank data collection, writing of the manuscript and the direction of all the work was done under HS, the main author.
###end p 51
###begin title 52
Pre-publication history
###end title 52
###begin p 53
The pre-publication history for this paper can be accessed here:
###end p 53
###begin p 54

###end p 54
###begin title 55
Supplementary Material
###end title 55
###begin title 56
Additional file 1
###end title 56
###begin p 57
###xml 0 7 0 7 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Table 1</bold>
###xml 59 67 <span type="species:ncbi:9606">patients</span>
Table 1. Overview on the detailed clinical data of all HHT patients.
###end p 57
###begin p 58
Click here for file
###end p 58
###begin title 59
Additional file 2
###end title 59
###begin p 60
###xml 0 7 0 7 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Table 2</bold>
Table 2. Diagnostic criteria according to the Curacao criteria for the diagnosis of HHT.
###end p 60
###begin p 61
Click here for file
###end p 61
###begin title 62
Additional file 3
###end title 62
###begin p 63
###xml 0 7 0 7 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Table 3</bold>
###xml 65 69 65 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
###xml 73 80 73 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
Table 3. Primers used in PCR-SSP genotyping for mutations in the ENG and ACVRL1 genes.
###end p 63
###begin p 64
Click here for file
###end p 64
###begin title 65
Additional file 4
###end title 65
###begin p 66
###xml 0 7 0 7 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Table 4</bold>
###xml 48 52 48 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG </italic>
Table 4. Summary of mutations identified in the ENG gene.
###end p 66
###begin p 67
Click here for file
###end p 67
###begin title 68
Additional file 5
###end title 68
###begin p 69
###xml 0 7 0 7 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Table 5</bold>
###xml 26 29 26 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ENG</italic>
Table 5. Polymorphisms in ENG.
###end p 69
###begin p 70
Click here for file
###end p 70
###begin title 71
Additional file 6
###end title 71
###begin p 72
###xml 0 7 0 7 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Table 6</bold>
###xml 48 55 48 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ACVRL1 </italic>
Table 6. Summary of mutations identified in the ACVRL1 gene.
###end p 72
###begin p 73
Click here for file
###end p 73
###begin title 74
Additional file 7
###end title 74
###begin p 75
###xml 0 7 0 7 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Table 7</bold>
###xml 47 55 <span type="species:ncbi:9606">patients</span>
Table 7. Genotype-phenotype correlation in HHT patients with confirmed mutation.
###end p 75
###begin p 76
Click here for file
###end p 76
###begin title 77
Acknowledgements
###end title 77
###begin p 78
###xml 23 31 <span type="species:ncbi:9606">patients</span>
We are indebted to the patients and their families and relatives for their participation. We would like to thank Petra Prohaska and Gabi Rink for excellent technical assistance.
###end p 78
###begin article-title 79
Hereditary hemorrhagic telangiectasia
###end article-title 79
###begin article-title 80
Novel mutations and polymorphisms in genes causing hereditary hemorrhagic telangiectasia
###end article-title 80
###begin article-title 81
###xml 29 37 <span type="species:ncbi:9606">patients</span>
Gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia
###end article-title 81
###begin article-title 82
Clinical manifestations of hereditary hemorrhagic telangiectasia
###end article-title 82
###begin article-title 83
###xml 101 109 <span type="species:ncbi:9606">patients</span>
Prevalence of pulmonary arteriovenous malformations (PAVMs) and occurrence of neurologic symptoms in patients with hereditary haemorrhagic telangiectasia (HHT)
###end article-title 83
###begin article-title 84
Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms
###end article-title 84
###begin article-title 85
Hepatic involvement in hereditary haemorrhagic telangiectasia: clinical, radiological, and hemodynamic studies of 11 cases
###end article-title 85
###begin article-title 86
###xml 17 25 <span type="species:ncbi:9606">patients</span>
Liver disease in patients with hereditary hemorrhagic telangiectasia
###end article-title 86
###begin article-title 87
Hereditary hemorrhagic telangiectasia: an update on clinical manifestations and diagnostic measures
###end article-title 87
###begin article-title 88
Ultrastructure and three-dimensional organization of the teleangiectases of hereditary hemorrhagic teleangiectasia
###end article-title 88
###begin article-title 89
Ultrastructure of hereditary hemorrhagic telangiectasia
###end article-title 89
###begin article-title 90
Pulmonary arteriovenous malformations: how do we diagnose them and why is it important to do so?
###end article-title 90
###begin article-title 91
Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome)
###end article-title 91
###begin article-title 92
A disease locus for hereditary haemorrhagic telangiectasia maps to chromosome 9q33-34
###end article-title 92
###begin article-title 93
A gene for hereditary haemorrhagic telangiectasia maps to chromosome 9q3
###end article-title 93
###begin article-title 94
Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1
###end article-title 94
###begin article-title 95
Genotype-phenotype relationship in hereditary haemorrhagic telangiectasia
###end article-title 95
###begin article-title 96
genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2
###end article-title 96
###begin article-title 97
Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2
###end article-title 97
###begin article-title 98
Hepatic manifestation is associated with ALK1 in hereditary hemorrhagic telangiectasia: identification of five novel ALK1 and one novel ENG mutations
###end article-title 98
###begin article-title 99
Endoglin, an ancillary TGFbeta receptor, is required for extraembryonic angiogenesis and plays a key role in heart development
###end article-title 99
###begin article-title 100
Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis
###end article-title 100
###begin article-title 101
Expression analysis of four endoglin missense mutations suggests that haploinsufficiency is the predominant mechanism for hereditary hemorrhagic telangiectasia type 1
###end article-title 101
###begin article-title 102
A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5
###end article-title 102
###begin article-title 103
A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7
###end article-title 103
###begin article-title 104
A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4)
###end article-title 104
###begin article-title 105
Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease
###end article-title 105
###begin article-title 106
###xml 62 70 <span type="species:ncbi:9606">patients</span>
High frequency of ENG and ALK1/ACVRL1 mutations in German HHT patients
###end article-title 106
###begin article-title 107
The variable number of tandem repeat polymorphism in the P-selectin glycoprotein ligand-1 gene is not associated with coronary heart disease
###end article-title 107
###begin article-title 108
###xml 68 73 <span type="species:ncbi:9606">human</span>
Optimized sensitivity of allele-specific PCR for prenatal typing of human platelet alloantigen single nucleotide polymorphisms
###end article-title 108
###begin article-title 109
Novel mutations in ENG and ACVRL1 identified in a series of 200 individuals undergoing clinical genetic testing for hereditary hemorrhagic telangiectasia HHT): correlation of genotype with phenotype
###end article-title 109
###begin article-title 110
###xml 62 70 <span type="species:ncbi:9606">patients</span>
Distribution of ENG and ACVRL1 (ALK1) mutations in French HHT patients
###end article-title 110
###begin article-title 111
Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: data from the French-Italian HHT network
###end article-title 111
###begin article-title 112
###xml 26 34 <span type="species:ncbi:9606">patients</span>
Mutation study of Spanish patients with hereditary hemorrhagic telangiectasia and expression analysis of Endoglin and ALK1
###end article-title 112
###begin article-title 113
###xml 26 34 <span type="species:ncbi:9606">patients</span>
Mutation study of Spanish patients with hereditary hemorrhagic telangiectasia
###end article-title 113
###begin article-title 114
Mutation analysis in hereditary haemorrhagic telangiectasia in Germany reveals 11 novel ENG and 12 novel ACVRL1/ALK1 mutations
###end article-title 114
###begin article-title 115
Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease
###end article-title 115
###begin article-title 116
Novel missense and frameshift mutations in the activin receptor-like kinase-1 gene in hereditary hemorrhagic telangiectasia. Mutations in brief no. 164
###end article-title 116
###begin article-title 117
Disease-associated mutations in conserved residues of ALK-1 kinase domain
###end article-title 117
###begin article-title 118
Molecular screening of ALK1/ACVRL1 and ENG genes in hereditary hemorrhagic telangiectasia in France
###end article-title 118

